In ATTAIN-MAINTAIN, patients who had plateaued after injectable therapy switched to oral orforglipron, marketed as Foundayo
Eli Lillys 18-month trial included more than 3,000 adults with an average starting weight of 228 pounds and a body mass index of 37, which is considered obese
This issue is further exacerbated by intratumoral and interlesional heterogeneity, whereby receptor expression can vary substantially not only between patients, but also across different tumor sites within the same individual
In some cases, it can cause aggression, feelings of anxiety and depression
Full text: Thomas-Valds, S., Tostes, M., Anunciao, P